Amoxicillin-clavulanic Acid for Treating Drug-resistant Mycobacterium Tuberculosis

Overview

Journal Chest

Publisher Elsevier

Specialty Pulmonary Medicine

Date 1991 Apr 1

PMID 1901260

Citations 38

Authors

J P Nadler

J Berger

J A Nord

R Cofsky

M Saxena

Affiliations

Soon will be listed here.

Abstract

This report describes two patients with multidrug resistant tuberculosis who were successfully treated with the addition of amoxicillin-clavulanic acid to second-line drugs. Mycobacterium tuberculosis possesses a beta-lactamase contributing to its resistance to beta-lactam antibiotics. The combination of clavulanic acid, a beta-lactamase inhibitor, and amoxicillin has been shown bactericidal for M tuberculosis in vitro. These data suggest that resistant tuberculosis may warrant a trial of treatment including amoxicillin-clavulanic acid.

Citing Articles

Identification of β-Lactams Active against by a Consortium of Pharmaceutical Companies and Academic Institutions.

Gold B, Zhang J, Lopez Quezada L, Roberts J, Ling Y, Wood M ACS Infect Dis. 2022; 8(3):557-573.

PMID: 35192346 PMC: 8922279. DOI: 10.1021/acsinfecdis.1c00570.

Repurposing Immunomodulatory Drugs to Combat Tuberculosis.

Fatima S, Bhaskar A, Dwivedi V Front Immunol. 2021; 12:645485.

PMID: 33927718 PMC: 8076598. DOI: 10.3389/fimmu.2021.645485.

Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Nahid P, Mase S, Migliori G, Sotgiu G, Bothamley G, Brozek J Am J Respir Crit Care Med. 2019; 200(10):e93-e142.

PMID: 31729908 PMC: 6857485. DOI: 10.1164/rccm.201909-1874ST.

Revisiting the β-Lactams for Tuberculosis Therapy with a Compound-Compound Synthetic Lethality Approach.

Xiao S, Guo H, Weiner W, Maddox C, Mao C, Gunosewoyo H Antimicrob Agents Chemother. 2019; 63(11).

PMID: 31427291 PMC: 6811440. DOI: 10.1128/AAC.01319-19.

Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.

Clemens D, Lee B, Silva A, Dillon B, Maslesa-Galic S, Nava S PLoS One. 2019; 14(5):e0215607.

PMID: 31075149 PMC: 6510528. DOI: 10.1371/journal.pone.0215607.